Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 184

The DOI matches its Crossref record.

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype

Open access
Scholz, Ina, Oberwittler, Heike, Riedel, Klaus‐Dieter, Burhenne, Jürgen, Weiss, Johanna, Haefeli, Walter E., Mikus, Gerd · 2009 · British Journal of Clinical Pharmacology

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Pharmacokinetic variability of voriconazole is largely caused by CYP3A4‐ and CYP2C19‐mediated metabolism. • Oral bioavailability of voriconazole has been claimed to be almost 100%, thus facilitating a change from intravenous to oral application without dose adjustment. WHAT THIS STUDY ADDS • For the first time voriconazole exposure after intravenous and oral administration in relation to CYP2C19 activity is reported. • In addition, the predominant metabolic pathway is the hydroxylation that seems to be influenced by the CYP2C19 genotype. • Enterohepatic circulation of both hydroxylated metabolites must be anticipated. AIMS The aim was to determine the pharmacokinetics of voriconazole after a single oral dose in comparison with intravenous (i.v.) administration in healthy individuals stratified according to the cytochrome P450 (CYP) 2C19 genotype. In addition, the possible metabolic pathways and their modulation according to CYP2C19 genotype were investigated after oral and i.v. administration of voriconazole. METHODS In a single‐centre, open‐label, two‐period crossover study 20 participants received single doses of 400 mg voriconazole orally and 400 mg voriconazole intravenously in randomized order. Blood and urine samples were collected up to 96 h post dose and the voriconazole and three major metabolites were quantified by high‐performance liquid chromatography coupled to mass spectroscopy. RESULTS Absolute oral bioavailability of voriconazole was 82.6% (74.1, 91.0). It ranged from 94.4% (78.8, 109.9) in CYP2C19 poor metabolizers to 75.2% (62.9, 87.4) in extensive metabolizers. In contrast to voriconazole and its N‐oxide, the plasma concentrations of both hydroxylated metabolites showed a large second peak after 24 h. Independent of the route of administration, voriconazole partial metabolic hydroxylation after i.v. administration was eightfold higher compared with N‐oxidation [48.8 ml min−1(30.5, 67.1)vs.6.1 ml min−1(4.1, 8.0)]. The formation of the metabolites was related to CYP2C19 activity. CONCLUSIONS Independent of the route of administration, voriconazole exposure was three times higher in CYP2C19 poor metabolizers compared with extensive metabolizers. Voriconazole has a high bioavailability with no large differences between the CYP2C19 genotypes. The hydroxylation pathway of voriconazole elimination exceeded the N‐oxidation, both influenced by the CYP2C19 genotype.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2009.03534.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 184

Metadata

Authors
Scholz, I., Oberwittler, H., Riedel, K., Burhenne, J., Weiss, J., Haefeli, W. E., & Mikus, G.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2009-11-27
Volume
68
Issue
6
Pages
906-915
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1985282417
Cited by
184
References
0
FWCI
6.20
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. https://app.cochat.ai/papers/10.1111/j.1365-2125.2009.03534.x
The paper
Scholz, I., Oberwittler, H., Riedel, K., Burhenne, J., Weiss, J., Haefeli, W. E., & Mikus, G. (2009). Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2009.03534.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.